19 Facts About Actelion

Actelion is a pharmaceuticals and biotechnology company established in December 1997, headquartered in Allschwil near Basel, Switzerland.

Actelion focuses on the manufacture of drugs that treat rare diseases and orphan diseases.

One of the focuses of Actelion is treating individuals with pulmonary arterial hypertension, a heart condition that leaves patients with a short life expectancy even with treatment.

Actelion scientists were among the first to work in the field of endothelian receptor antagonists.

Actelion was initially financed with venture capital provided through a syndicate including Atlas Venture, Sofinnova and HealthCap.

Related searches

Actelion develops and sells drugs in the continents of Asia, Europe and North and South America.

Actelion has 29 operative affiliates around the world, including in the United States, Canada, Brazil, Australia, Japan, Switzerland and a number of EU countries.

Actelion was founded in 1997 by husband and wife team Jean-Paul and Martine Clozel together with three colleagues after F Hoffmann-La Roche cut their funding for Martine's cardiovascular program.

In November 2006, CoTherix and Actelion signed a merger plan, which was announced publicly; this followed the initiation of negotiations in August 2006.

In January 2007, Actelion completed acquisition of all CoTherix stock, and summarily informed Asahi that work on fasudil would be terminated.

Now, Actelion had a competitor blockbuster drug on the market, bosentan .

Actelion was able to do this by illegally providing money to Medicare patients in order for them to be able to fulfill their co-payments for the drug Tracleer.

Actelion was able to use the charity organization by the name of Caring Voice Coalition to send money only to those people who were receiving prescriptions of Tracleer.

Actelion was complicit in referring patients to Caring Voice Coalition.

Actelion has been reported to start working with Analytics 4 Life to use imaging technology with regards to pulmonary hypertension.

Actelion currently has 10 compounds in its pipeline – including 3 in late-stage development – and 4 medicines on the market for orphan diseases:.

Actelion's shares have been listed on the SIX Swiss Exchange since 2000 SWX Swiss Exchange Swiss Leader Index.

In September 2008, Actelion shares began trading as part of the Swiss Market Index.

Actelion received the "Prix Hermes de l'innovation" in April 2011: The "European Institute for Creative Strategy and Innovation", the creator of the Prix Hermes, was founded in 2003 in France.